dapagliflozin

Overview

Dapagliflozin is a small-molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor used as a pharmacologic target in studies of diabetes and cardiorenal disease. By inhibiting SGLT2 in the kidney, it reduces renal glucose reabsorption and promotes urinary glucose excretion, thereby improving glycemic control. Beyond glucose lowering, dapagliflozin has been investigated for broader effects on kidney, heart, vascular, and inflammatory pathways, including oxidative stress, inflammation, fibrosis, apoptosis, and cellular senescence.

In biomedical research, dapagliflozin is frequently studied in the context of type 1 diabetes, type 2 diabetes, diabetic nephropathy/diabetic kidney disease, kidney failure, and myocardial injury models. Experimental and translational work has also examined its impact on molecular processes such as Transforming growth factor, beta 1 signaling, endothelial cell responses, and metabolic stress in the kidney. These studies position dapagliflozin as a representative sodium-glucose cotransporter-2 inhibitor with relevance beyond glycemic control.

Recent Publications Summary

Recent studies have continued to evaluate dapagliflozin across a range of preclinical and translational settings, most often in kidney disease and cardiometabolic injury. In youth with type 1 diabetes and hyperfiltration, a placebo-controlled trial assigned participants to dapagliflozin or placebo for 16 weeks and paired treatment with sequential kidney biopsies, kidney MRI, and proteomic analyses; single-cell RNA sequencing showed coordinated transcriptional shifts across nephron, vascular, and immune compartments, with dapagliflozin down-regulating glycolysis, gluconeogenesis, and oxidative stress markers in proximal tubule cells, while endothelial cells showed reduced profibrotic and inflammatory gene expression and increased protective factors 42485434Jul. In diabetic kidney disease, mechanistic work linked glucotoxic stress, CTRP1, and SGLT2-mediated glucose uptake, supporting a role for SGLT2 inhibition in attenuating renal tubular senescence 42461151Jul. Additional studies in streptozotocin-induced diabetes in rats found that dapagliflozin reduced glucose levels and, in combination with liraglutide, produced the strongest glycemic effect, while renal inflammatory and oxidant markers were elevated in diabetes and only partially improved by treatment 42341385Jun.

Other publications examined dapagliflozin in combination strategies or in alternative disease models. In diabetic kidney disease models using streptozotocin-treated rats and HG+TGF-β1-stimulated NRK-52E cells, recombinant human klotho plus dapagliflozin improved metabolic and renal function and preserved renal architecture, with increased markers of mitophagy-related pathways and reduced apoptosis and fibrosis 42172900May. In dialysis patients with CKD, a predefined post-hoc analysis of a randomized trial assessed dapagliflozin 10 mg daily versus standard care over 24 weeks, focusing on serum Klotho, FGF23, and other bone biomarkers as well as fractures, osteopenia, and osteoporosis 42595915Aug. In mice with early diet-induced cardiovascular-kidney-metabolic syndrome, dapagliflozin was tested after high-fat diet exposure to assess sex-specific metabolic, cardiac, and renal responses 42411797Jul.

Beyond kidney-focused work, dapagliflozin has also been explored in cardiovascular and ophthalmic contexts. A study of myocardial ischemia/reperfusion injury reported that dapagliflozin ameliorated injury through modulation of EGFR signaling and targeting NCOA4-mediated ferritinophagy 41644044Feb. In glaucoma research, dapagliflozin was incorporated into polymeric nanomicelles to improve ocular delivery, with the formulation showing favorable size, morphology, entrapment efficiency, and sustained release in preliminary testing 42331119Jun.

What Changes, What Holds

1. Transcriptional profiling shows dapagliflozin reprograms diabetic kidney disease toward lower stress and less fibrosis
REINFORCES Single-cell and biopsy-linked profiling strengthens the established view that dapagliflozin acts beyond glucose lowering in the kidney, with coordinated effects on proximal tubular metabolism, endothelial activation, and immune/inflammatory signaling 42485434Jul. The new work does not overturn the baseline account; it sharpens it by mapping cell-type-specific correlates of the kidney-protective phenotype and by linking SGLT2 inhibition to reduced senescence-associated stress pathways in diabetic kidney disease 42461151Jul.

2. Combination and adjunct studies extend dapagliflozin into bone-mineral and multimodal kidney-cardiometabolic questions
NEW DIRECTION Dapagliflozin is being pushed into roles the Overview does not cover, including bone-mineral biology in dialysis-associated CKD and sex-specific responses in early cardiovascular-kidney-metabolic syndrome 42595915Aug42411797Jul. These studies do not contradict the baseline, but they broaden the entity from a kidney-and-glycemia tool toward a modifier of mineral metabolism and whole-syndrome adaptation. The combination with klotho also suggests additive renal protection, yet remains mechanistic rather than practice-changing 42172900May.

3. Dapagliflozin is now being explored as a mechanistic candidate in cardiac injury and a formulation payload in eye disease
NEW DIRECTION Myocardial ischemia/reperfusion and glaucoma delivery work move dapagliflozin into areas the Overview does not address, so these are expansions rather than revisions of its established SGLT2-inhibition story 41644044Feb42331119Jun. The cardiac study suggests a plausible injury-modulating mechanism, while the nanomicelle formulation is mainly a drug-delivery advance. Together they hint at broader translational use, but neither yet establishes a new standard indication or displaces the kidney-centered baseline.

Overview update candidates: dapagliflozin may merit mention of transcriptional and cell-type-specific kidney effects in diabetic kidney disease; plus exploratory work in bone-mineral metabolism; cardiovascular-kidney-metabolic syndrome; myocardial ischemia/reperfusion; and ocular delivery strategies.